Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
News|Articles|April 21, 2025
AUA 2025: What to watch for in urologic oncology
Fact checked by: Hannah Clarke
We preview several noteworthy P2 presentations in the urologic oncology space.
Advertisement
Advertisement
The American Urological Association (AUA) will try its luck in Las Vegas, Nevada for its 2025 annual meeting. Taking place at the Venetian Las Vegas from April 26-29 (and preceded by the AUA Innovation Nexus on April 25), the meeting will feature scientific abstracts, lectures, Crossfire Debates, the P2s: Practice-changing Paradigm-shifting Clinical Trials in Urology, and much more. In this article, we preview several noteworthy P2 presentations in the urologic oncology space. You can follow Urology Times’ coverage of the meeting
Related to this article
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The agency issued a PDUFA target action date of June 14, 2027.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Advertisement
Advertisement